Lymphoma

P=N/A, N=135, Completed, Institut Paoli-Calmettes | Active, not recruiting --> Completed

P2, N=23, Active, not recruiting, ImmuneOncia Therapeutics Inc. | Trial completion date: Feb 2026 --> Feb 2027

P2, N=20, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

P1/2, N=161, Recruiting, AstraZeneca | N=110 --> 161 | Trial completion date: May 2026 --> Apr 2029 | Trial primary completion date: May 2026 --> Apr 2029

P=N/A, N=300, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P1/2, N=50, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Dec 2026

P=N/A, N=30, Not yet recruiting, Sun Yat-sen University

P=N/A, N=85, Not yet recruiting, University Hospital, Limoges

Treatment-emergent adverse events (TEAEs) led to treatment discontinuation in 16.0% of patients with CR; the most common TEAE was cytokine release syndrome (56.4%). This generally manageable safety profile and the sustainability of CRs support odronextamab as a potential long-term treatment for heavily pretreated R/R FL.

We also demonstrated that, compared with that with each drug used as single agents, the combined 5-aza and HDAC3i treatment induced the epigenetic remodeling of DLBCL cells, which resulted in a more potent reexpression of differentiation genes, including XBP1 and ATF4. Our results highlight the importance of specifically targeting multiple layers of the epigenome to maximize the efficacy of epigenetic-based therapies.